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L E T T E R  T O  T H E  E D I T O R
ARIA-EAACI statement on asthma and COVID-19 (June 2, 
2020)
To the Editor,
A novel strain of human coronaviruses, the severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2), named by the 
International Committee on Taxonomy of Viruses (ICTV),1 has re-
cently emerged and caused an infectious disease. This disease is re-
ferred to as the “coronavirus disease 2019” (COVID-19) by the World 
Health Organization (WHO).2
The US Centers for Disease Control and Prevention (CDC) have 
proposed that “People with moderate to severe asthma may be at 
higher risk of getting very sick from COVID-19. COVID-19 can affect 
your respiratory tract (nose, throat, lungs), cause an asthma attack 
and possibly lead to pneumonia and acute respiratory disease.” (May 
24, 2020). (https://www.cdc.gov/coron aviru s/2019-ncov/need-ex-
tra -preca ution s/asthma.html) On the other hand, in the UK, NICE 
proposes rapid guidelines for severe asthma (https://www.guide 
lines.co.uk/covid -19-rapid -guide line-sever e-asthm a/455275.article).
An ARIA-EAACI statement has been devised to make recom-
mendations on asthma, and not necessarily on severe asthma, based 
on a consensus from its members.
It is difficult in many studies to clearly assess the prevalence of 
asthma on COVID-19 since most patients are older adults and prob-
ably have multimorbidities. Most studies do not clarify whether 
asthmatic patients with COVID-19 have isolated asthma or asthma 
as a multimorbidity, particularly in the context of hypertension, obe-
sity and diabetes. In particular, obesity is a significant risk factor for 
COVID-19 and its severity,3 and may be intertwined with asthma.
In some studies, showing data mostly on critically ill patients, 
there does not appear to be an increased prevalence of asthma.4-7 
In Wuhan, the prevalence of asthma in COVID-19 patients was 
0.9%, markedly lower than that of the general adult population of 
this city.8 Differently, in New York, among 5,700 hospitalized pa-
tients with COVID-19, asthma prevalence was 9% and COPD 4.5%.9 
In California, 7.4% of the 377 hospitalized patients had asthma or 
COPD.10 The US CDC reported that between March 1st and 30th 
2020, among COVID-NET hospitals from 99 counties and 14 states 
(an open source neural network for COVID-19 infection), chronic 
lung disease (primarily asthma) was the second most prevalent co-
morbid condition for hospitalized patients aged 18-49 years with 
laboratory-confirmed COVID-19.11 Among the 17% of COVID-19-
positive patients with an underlying history of asthma, the incidence 
was at its highest in younger adults (27% in the 18- to 49-year-
old group). The UK experience on over 20, 133 hospitalized cases 
shows that 14% of admissions were patients with asthma.12 In the 
OpenSAFELY Collaborative Study (UK), an increased risk of severe 
COVID-19, including death, was found in patients with asthma, par-
ticularly related with a recent use of oral corticosteroid.13 A review 
with all identified studies up to 5 May 2020 is available.14 However, 
low socioeconomic status, obesity, non-white ethnicity, chronic re-
spiratory disease and diabetes had stronger signals.
Some anti-asthma medications, such as ciclesonide, might have a 
beneficial effect on COVID-19.15
Thus, whether patients with asthma are at a higher or lower 
risk of acquiring COVID-19 may depend on geography, age, other 
multimorbidities, different air quality,16 genetic predispositions, 
ethnicity, social behaviour, access to health care or other factors. 
Moreover, the current information is obtained mainly from hospi-
talization or intensive care unit data. Real-life data in a non-selected 
population of asthmatics are needed to better understand the links 
between asthma and SARS-Cov-2 in terms of both incidence and 
severity.
Asthma does not seem to be a risk factor for severe COVID-19 
but patients treated with oral corticosteroids may be at a higher risk 
of severe COVID-19.14 However, a large study is needed to fully ap-
preciate the relationship between COVID-19 and severe asthma.
According to the IPCRG (International Primary Care Respiratory 
Group), patients are still struggling to differentiate their symptoms 
between asthma flare-ups and COVID-19. They may therefore delay 
seeking care for asthma or COVID-19. Interestingly, clarity does not 
appear to have improved as the weeks have passed. People have 
recurrences or waves of repeated symptoms, and it is difficult to un-
derstand whether the symptoms are related to an asthma exacerba-
tion or to COVID-19.
According to the IPCRG, many clinicians tend to prescribe anti-
biotics to people who they believe are having asthma exacerbations 
“just to be safe.” They focus on the potential infection element of the 
trigger more than the asthma management itself. It would seem that 
COVID-19 might exacerbate this behaviour, not improve it.
In areas where COVID-19 is prevalent, GPs are still very con-
cerned about oral—and, to a certain degree, inhaled—corticoste-
roids, possibly because they use remote models of care. They are 
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reluctant to prescribe higher doses of ICS or OCS as they fear they 
cannot tell the difference between a flare-up and COVID-19.
The extent of expression in the upper and lower airways of the 
SARS-CoV-2 entry receptors, angiotensin-converting enzyme 2 
(ACE2) and TMPRSS2, might impact the clinical severity of COVID-
19. ACE-2 was found to be decreased in patients with allergic 
asthma17 or in those receiving inhaled corticosteroids.18 These data 
suggest that this expression may be a potential contributor, among 
F I G U R E  1   Geographic representation of the experts
1 In areas where COVID-19 is prevalent, screening protocols for COVID- 19 should be 
applied to anyone having worsening respiratory symptoms, and personal protective 
equipment should be used.
2 In areas where COVID-19 is prevalent, lung function testing procedures should be 
postponed if not deemed absolutely necessary; portable personal devices measuring 
PEF and FEV1 can be used in the meantime to monitor asthma control using the 
telemedicine approach.
3 In accordance with the Global Initiative for Asthma (GINA) (https://ginas thma.org/recom 
menda tions -for-inhal ed-asthm a-contr oller -medic ation s/), patients with asthma should 
not stop their prescribed inhaled corticosteroid controller medication (or prescribed oral 
corticosteroids). Stopping inhaled corticosteroids may have serious consequences.
4 Long-term oral corticosteroids may sometimes be required to treat severe asthma, and it 
may be dangerous to stop them suddenly (GINA).
5 Oral steroids should continue to be used to treat severe asthma exacerbations.
6 In patients infected by SARS-CoV-2 (symptomatic or asymptomatic), nebulization (which 
increases the risk of deposition of the virus into the lower airways) should be replaced by 
spacers of large capacity.
7 In accordance with the NICE, in non-SARS-CoV-2 infected patients, we propose(https://
www.nice.org.uk/guida nce/ng166/ chapt er/3-Treat ment#patie nts-havin g-biolo gical -treat 
ment):
• To continue biologics because there is no evidence that biological therapies for asthma 
suppress immunity
• If the patient usually attends a hospital for biological treatments, to think about if he/
she can be trained to self-administer or could be treated at a community clinic or at 
home
• To carry out routine monitoring of biological treatment remotely if possible
8 In SARS-CoV-2-infected patients, in accordance with the EAACI, we propose to cease the 
treatment until resolution of the disease is established. Thereafter, the administration of 
the biological should be re-initiated.
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several other factors, to reduced COVID-19 severity in patients with 
T2 inflammation.17,19 However, ACE-2 expression in asthma patients 
was increased in African Americans, in males and in association with 
diabetes.
Finally, a recent study which analysed the nasal transcriptome of 
695 children suggested that the strongest determinants of airway 
ACE2 and TMPRSS2 expression are T2 inflammation and viral-in-
duced interferon inflammation. However, this study specifically 
showed that T2 inflammation (via IL-13) impacted differentially on 
ACE2 and TMPRSS2, with a T2-high phenotype being associated 
with a highly significant decrease in the former and a significant de-
crease in the latter receptor. Thus, although SARS-CoV-2-specific 
analyses and experiments are lacking, the differential effects of 
T2-inflammation on ACE2 and TMPRSS2 reported in this study war-
rant further research on whether T2-high and T2-low asthma phe-
notypes may be associated with differential susceptibility to severe 
COVID-19.
The first author developed seven recommendations that were 
sent for comment to 105 experts around the world . 69 answers 
were received within 48 hours, and the comments were considered. 
Where experts suggested modification of the recommendations, a 
discussion was initiated and recommendations modified until con-
sensus was reached. After these modifications, a total of 9 recom-
mendations were proposed for a second round. In the second round, 
145 experts were invited to comment on and approve or reject the 
recommendations. 78 answers were received within 48 hours and, 
when an agreement of over 80/100 was reached, the question was 
included in the statement.
The same approach was used for the research questions. Two 
research needs were dropped.
The geographic distribution of the experts is given in Figure 1. 
They were from 43 countries.
ARIA-EAACI statement (Table 1).
ARIA-EAACI research questions (Table 2).
This view is pragmatic, cautious and based upon expert opinion. 
However, it is likely to require modifications as further evidence is 
gathered. These recommendations are conditional and should be 
adapted regularly on the basis of evolving clinical evidence.
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